[go: up one dir, main page]

WO2008061978A3 - Moyens et procédés d'optimisation d'approches diagnostiques et thérapeutiques dans une maladie artérielle chronique basés sur la troponine t et le nt-probnp - Google Patents

Moyens et procédés d'optimisation d'approches diagnostiques et thérapeutiques dans une maladie artérielle chronique basés sur la troponine t et le nt-probnp Download PDF

Info

Publication number
WO2008061978A3
WO2008061978A3 PCT/EP2007/062562 EP2007062562W WO2008061978A3 WO 2008061978 A3 WO2008061978 A3 WO 2008061978A3 EP 2007062562 W EP2007062562 W EP 2007062562W WO 2008061978 A3 WO2008061978 A3 WO 2008061978A3
Authority
WO
WIPO (PCT)
Prior art keywords
troponin
diagnostic
cardiac
methods
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2007/062562
Other languages
English (en)
Other versions
WO2008061978A2 (fr
Inventor
Georg Hess
Andrea Horsch
Dietmar Zdunek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Roche Diagnostics GmbH
Original Assignee
F Hoffmann La Roche AG
Roche Diagnostics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP06124479A external-priority patent/EP1925943A1/fr
Application filed by F Hoffmann La Roche AG, Roche Diagnostics GmbH filed Critical F Hoffmann La Roche AG
Priority to JP2009536751A priority Critical patent/JP5306218B2/ja
Priority to EP07847226A priority patent/EP2089719A2/fr
Publication of WO2008061978A2 publication Critical patent/WO2008061978A2/fr
Publication of WO2008061978A3 publication Critical patent/WO2008061978A3/fr
Priority to US12/465,825 priority patent/US8361800B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des moyens et des procédés diagnostiques. Spécifiquement, la présente invention comprend un procédé destiné à diagnostiquer la cause d'une nécrose cardiaque chez un sujet comprenant la détermination de la quantité de troponine cardiaque et de la quantité d'un peptide de type BNP dans un échantillon d'un sujet souffrant de nécrose cardiaque et la comparaison de la quantité de ladite troponine cardiaque et de la quantité dudit peptide de type BNP à des quantités de référence, moyennant quoi la cause de la nécrose cardiaque sera diagnostiquée. La présente invention concerne en outre un procédé de détermination du fait qu'un sujet souffrant de nécrose cardiaque est sensible ou non à une thérapie contre une insuffisance cardiaque initiale et un procédé de détermination du fait qu'un sujet souffrant d'une nécrose cardiaque est sensible ou non à une thérapie contre une maladie coronarienne. Les utilisations, dispositifs et kits diagnostiques sont également compris.
PCT/EP2007/062562 2006-11-21 2007-11-20 Moyens et procédés d'optimisation d'approches diagnostiques et thérapeutiques dans une maladie artérielle chronique basés sur la troponine t et le nt-probnp Ceased WO2008061978A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2009536751A JP5306218B2 (ja) 2006-11-21 2007-11-20 トロポニンＴおよびＮＴ−ｐｒｏＢＮＰの検出に基づく慢性動脈疾患での診断および治療的アプローチの最適化のための手段および方法
EP07847226A EP2089719A2 (fr) 2006-11-21 2007-11-20 Moyens et procédés d'optimisation d'approches diagnostiques et thérapeutiques dans une maladie artérielle chronique basés sur la troponine t et le nt-probnp
US12/465,825 US8361800B2 (en) 2006-11-21 2009-05-14 Diagnostic means and methods using troponin T and NT-proBNP

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP06124479A EP1925943A1 (fr) 2006-11-21 2006-11-21 Moyens et procédés pour l'optimisation de la diagnose et de la thérapie pour les artériopathies chroniques basés sur la détection de la troponin T et la NT-proBNP.
EP06124479.4 2006-11-21
EP07101946.7 2007-02-08
EP07101946 2007-02-08

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/465,825 Continuation US8361800B2 (en) 2006-11-21 2009-05-14 Diagnostic means and methods using troponin T and NT-proBNP

Publications (2)

Publication Number Publication Date
WO2008061978A2 WO2008061978A2 (fr) 2008-05-29
WO2008061978A3 true WO2008061978A3 (fr) 2008-07-10

Family

ID=38984314

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/062562 Ceased WO2008061978A2 (fr) 2006-11-21 2007-11-20 Moyens et procédés d'optimisation d'approches diagnostiques et thérapeutiques dans une maladie artérielle chronique basés sur la troponine t et le nt-probnp

Country Status (3)

Country Link
EP (1) EP2089719A2 (fr)
JP (1) JP5306218B2 (fr)
WO (1) WO2008061978A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9983213B2 (en) 2008-07-23 2018-05-29 Roche Diagnostics Operations, Inc. Identification of subjects being susceptible to anti-angiogenesis therapy
US10942175B2 (en) 2010-08-26 2021-03-09 Roche Diagnostics Operations, Inc. Use of biomarkers in the assessment of the early transition from arterial hypertension to heart failure

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011528798A (ja) * 2008-07-23 2011-11-24 エフ．ホフマン−ラ ロシュ アーゲー 抗血管形成療法のモニター
RU2423072C1 (ru) * 2009-11-19 2011-07-10 Федеральное государственное учреждение "Ивановский научно-исследовательский институт материнства и детства имени В.Н. Городкова Федерального агентства по высокотехнологичной медицинской помощи" Способ прогнозирования исхода постгипоксических нарушений сердечно-сосудистой системы у новорожденных
EP2730923A1 (fr) * 2012-11-09 2014-05-14 Roche Diagniostics GmbH Orientation de thérapie à base de cTnT et NtproBNP pour l'insuffisance cardiaque
EP3470848A3 (fr) 2014-01-28 2019-05-22 Roche Diagnostics GmbH Biomarqueurs pour l'évaluation de risques et la surveillance thérapeutique chez des patients atteints d'insuffisance cardiaque guidée par des peptides natriurétiques
IT202100011327A1 (it) * 2021-05-04 2022-11-04 Gek S R L Metodo prognostico

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004045381A2 (fr) * 2002-11-18 2004-06-03 Princeton Biomeditech Corporation Dispositif de dosage immunologique permettant le diagnostic d'une insuffisance cardiaque globale et la prediction de la mortalite en cas d'insuffisance cardiaque globale
US20060183681A1 (en) * 2005-02-14 2006-08-17 Bio-Rad Laboratories, Inc. Stabilized compositions containing natriuretic peptides

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9211686D0 (en) * 1992-06-03 1992-07-15 Medisinsk Innovation A S Chemical compounds
US7632647B2 (en) * 2001-04-13 2009-12-15 Biosite Incorporated Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes
MXPA03004105A (es) * 2002-05-14 2004-10-15 Hoffmann La Roche Elaboracion de una prognosis en casos de enfermedad cardiaca usando una combinacion de marcadores.
JP2005294899A (ja) * 2004-03-31 2005-10-20 Victor Co Of Japan Ltd 光送信機
EP1890153A1 (fr) * 2006-08-16 2008-02-20 F. Hoffman-la Roche AG Troponine cardiaque servant d'indicateur de maladie avancée des artères coronaires

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004045381A2 (fr) * 2002-11-18 2004-06-03 Princeton Biomeditech Corporation Dispositif de dosage immunologique permettant le diagnostic d'une insuffisance cardiaque globale et la prediction de la mortalite en cas d'insuffisance cardiaque globale
US20060183681A1 (en) * 2005-02-14 2006-08-17 Bio-Rad Laboratories, Inc. Stabilized compositions containing natriuretic peptides

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
DE LEMOS JAMES A ET AL: "Combining natriuretic peptides and necrosis markers in the assessment of acute coronary syndromes.", REVIEWS IN CARDIOVASCULAR MEDICINE 2003, vol. 4 Suppl 4, 2003, pages S37 - S46, XP009078226, ISSN: 1530-6550 *
FONAROW GREGG C ET AL: "Combining natriuretic peptides and necrosis markers in determining prognosis in heart failure.", REVIEWS IN CARDIOVASCULAR MEDICINE 2003, vol. 4 Suppl 4, 2003, pages S20 - S28, XP009078137, ISSN: 1530-6550 *
HOURS S ET AL: "Value and interest of biological cardiac markers (BNP and troponin) in intensive care unit", REANIMATION 2004 FRANCE, vol. 13, no. 2, 2004, pages 112 - 119, XP002418274, ISSN: 1624-0693 *
KOH EIKAN ET AL: "Troponin-T and brain natriuretic peptide as predictors for adriamycin-induced cardiomyopathy in rats.", CIRCULATION JOURNAL : OFFICIAL JOURNAL OF THE JAPANESE CIRCULATION SOCIETY FEB 2004, vol. 68, no. 2, February 2004 (2004-02-01), pages 163 - 167, XP002418273, ISSN: 1346-9843 *
KRZEMINSKA-PAKULA M: "Biomarkers in acute coronary syndromes in women. Helpful for risk stratification and therapeutic decision-making?", POLSKI PRZEGLAD KARDIOLOGICZNY 2006 POLAND, vol. 8, no. 1, 2006, pages 41 - 44, XP009078221, ISSN: 1507-5540 *
RAVKILDE JAN: "Risk stratification of acute coronary syndrome patients. A multi-marker approach", SCANDINAVIAN JOURNAL OF CLINICAL AND LABORATORY INVESTIGATION, vol. 65, no. Suppl. 240, 2005, pages 25 - 29, XP009078395, ISSN: 0036-5513 *
See also references of EP2089719A2 *
TANIGUCHI RYOJI ET AL: "Combined measurements of cardiac troponin T and N-terminal pro-brain natriuretic peptide in patients with heart failure", CIRCULATION JOURNAL, vol. 68, no. 12, December 2004 (2004-12-01), pages 1160 - 1164, XP002418271, ISSN: 1346-9843 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9983213B2 (en) 2008-07-23 2018-05-29 Roche Diagnostics Operations, Inc. Identification of subjects being susceptible to anti-angiogenesis therapy
US10942175B2 (en) 2010-08-26 2021-03-09 Roche Diagnostics Operations, Inc. Use of biomarkers in the assessment of the early transition from arterial hypertension to heart failure

Also Published As

Publication number Publication date
JP2010510481A (ja) 2010-04-02
JP5306218B2 (ja) 2013-10-02
EP2089719A2 (fr) 2009-08-19
WO2008061978A2 (fr) 2008-05-29

Similar Documents

Publication Publication Date Title
WO2008061978A3 (fr) Moyens et procédés d'optimisation d'approches diagnostiques et thérapeutiques dans une maladie artérielle chronique basés sur la troponine t et le nt-probnp
Tsai et al. Interpretation and use of natriuretic peptides in non-congestive heart failure settings
Chao et al. The association between hyperuricemia, left atrial size and new-onset atrial fibrillation
Afsin Oktay et al. Diagnosis and management of heart failure with preserved ejection fraction: 10 key lessons
Jing et al. Pulmonary function testing in patients with pulmonary arterial hypertension
Bielecka-Dabrowa et al. Heart failure biomarkers in patients with dilated cardiomyopathy
Ratnasamy et al. Associations between neurohormonal and inflammatory activation and heart failure in children
DE602006014535D1 (de) Verwendung von nt-proanp und nt-probnp zur diagnose von herzerkrankungen
WO2010025393A3 (fr) Marqueurs biologiques protéiques et méthodes pour diagnostiquer la maladie de kawasaki
RU2014136453A (ru) Биомаркеры для диагностики, прогноза, оценки и стратификации терапии обмороков
WO2009029971A8 (fr) Procédé de diagnostic du syndrome métabolique
WO2008055242A4 (fr) Détection précoce du cancer
Gevaert et al. Endothelial dysfunction and cellular repair in heart failure with preserved ejection fraction: response to a single maximal exercise bout
Gentilini et al. Cardiovascular and renal function in normotensive and hypertensive patients with compensated cirrhosis: effects of posture
Palazzuoli et al. Current gaps in HFpEF trials: Time to reconsider patients' selection and to target phenotypes
WO2010138610A3 (fr) Nouveaux sites de phosphorylation de la desmine utiles dans le diagnostic de maladies cardiaques et l'intervention dans le cadre de ces maladies
McDonagh et al. Screening for asymptomatic left ventricular dysfunction using B‐type natriuretic peptide
WO2005071407A3 (fr) Methodes
WO2008125681A8 (fr) Moyens et procédés permettant d'évaluer le risque d'une intervention cardiaque chez des patients souffrant d'une maladie cardiaque coronarienne stable à partir de gdf-15
Popelová et al. Range and distribution of NT-proBNP values in stable corrected congenital heart disease of various types
Bolignano et al. Pulmonary hypertension: a neglected risk condition in renal patients?
Lizak et al. The influence of chronic heart failure on pulmonary function tests in patients undergoing orthotopic heart transplantation
Alghadir et al. Cellular fibronectin response to supervised moderate aerobic training in patients with type 2 diabetes
Magrì et al. Opposite behavior of plasma levels surfactant protein type B and receptor for advanced glycation end products in pulmonary sarcoidosis
Suciadi et al. Tachycardia and pre-existing chronic kidney disease are predictors of the worse clinical outcomes in patients recently hospitalized with acute heart failure

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07847226

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 09005359

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 2009536751

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2007847226

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE